Changes related to kidney staining in UUO mouse model. حسب Wencheng Jin (13136262)

National age-standardized rates of DALYs and ASDR of IHD attributable to HSBP and their estimated annual percentage changes in 2021. حسب Zhenhua Zhuang (11192745)

الموضوعات:

Changes associated with kidney fibrosis in TGF- حسب Wencheng Jin (13136262)

The screening process of MN705. حسب Wencheng Jin (13136262)

Validation of MN705 treatment effects in human proximal tubular epithelial cells during TGF- حسب Wencheng Jin (13136262)

Age-specific burden of IHD attributable to HSBP for males and females in 2021. حسب Zhenhua Zhuang (11192745)

الموضوعات:

Global burden of IHD attributable to HSBP from 1990 to 2021. حسب Zhenhua Zhuang (11192745)

الموضوعات:

Age-specific estimated annual percentage changes in DALYs and death rates for 21 regions from 1990 to 2021. حسب Zhenhua Zhuang (11192745)

الموضوعات:

SDI-based age-standardized rates of DALYs and ASDR for IHD attributable to HSBP. حسب Zhenhua Zhuang (11192745)

الموضوعات:

Effect of MN705 treatment on TGF- حسب Wencheng Jin (13136262)

Modeling the relationship between cancer level in hemolymph and MarBTN in tank eDNA. حسب Rachael M. Giersch (22331947)

Renal outcomes of both treatment groups. حسب Marwan El-Deyarbi (21688492)

"…</p><p>Results</p><p>During a mean follow-up of 11.9 months, 40.4% of the participants in the intervention group (31.6% in the control group) achieved diabetes control (HbA1c < 7%), with a significant mean difference of −0.36% in HbA1c levels between the groups (95% CI: −0.54 – −0.19, P < 0.01). …"

Supplementary Tables 1–8. حسب Juliane F. Tampé (19976538)

الموضوعات:

The characteristics and clinical features of 12 patients. حسب Masashi Okawa (8951294)

الموضوعات:

Effect of the VEGF-A–bevacizumab complex removal using immunoprecipitation on the concentrations of VEGF-A121, VEGF-A165, and VEGF-A. حسب Masashi Okawa (8951294)

الموضوعات:

Equation of the equilibrium dissociation constant of the antigen-antibody reaction. حسب Masashi Okawa (8951294)

الموضوعات:

The original data for the figures. حسب Masashi Okawa (8951294)

الموضوعات:

Blood concentrations of VEGF-A121, VEGF-A165, and VEGF-A pre- and post-bevacizumab administration. حسب Masashi Okawa (8951294)

الموضوعات:

VEGF-A121, VEGF-A165, and VEGF-A contents per unit platelets. حسب Masashi Okawa (8951294)

الموضوعات:

Neutralization with additional bevacizumab to serum samples pre- and post-bevacizumab administration. حسب Masashi Okawa (8951294)

الموضوعات: